N. Mentens

发表

Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia

Stein Aerts, Gert Hulselmans, Jan Cools, 2012, Nature Genetics.

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.

S. Demeyer, K. Jacobs, J. Cools, 2019, Blood.

An Examination of the Differential Sensitivity to Ketolide Antibiotics in ermB Strains of Streptococcus pyogenes and Streptococcus pneumoniae

N. Mentens, W. S. Champney, Kimberly Zurawick, 2004, Current Microbiology.

Advances in Brief Prediction of Resistance to Small Molecule FLT 3 Inhibitors : Implications for Molecularly Targeted Therapy of Acute Leukemia

D. Fabbro, P. Marynen, P. Furet, 2004 .

Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA.

P. Marynen, R. Sciot, M. Debiec‐Rychter, 2006, Gastroenterology.

Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13).

P. Marynen, A. Hagemeijer, M. Odero, 2002, Blood.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

P. Marynen, J. Cools, N. Mentens, 2006, Blood.

Sorafenib (BAY43-9006) is a potent inhibitor of FIP1L1-PDGFR α and the imatinib resistant FIP1L1-PDGFR α T674I mutant

P. Marynen, J. Cools, N. Mentens, 2006 .

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma

S. Ogawa, S. Demeyer, K. Jacobs, 2022, bioRxiv.

Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion

P. Marynen, D. Arthur, I. Lahortiga, 2008, Haematologica.

Generation of the Fip1l1–Pdgfra fusion gene using CRISPR/Cas genome editing

S. Demeyer, J. Cools, C. D. de Bock, 2016, Leukemia.

TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia

S. Demeyer, J. Cools, N. Mentens, 2022, Haematologica.

The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia

S. Demeyer, K. Jacobs, J. Cools, 2020, Clinical Cancer Research.

Oncogenic Cooperation Between IL7R-JAK-STAT Pathway Mutations

K. Jacobs, J. Cools, N. Mentens, 2021, HemaSphere.

EML1–ABL1 Is Activated by Coiled-Coil-Mediated Oligomerization and Induces T-Cell Acute Lymphoblastic Leukemia or Myeloproliferative Disease in a Mouse Bone Marrow Transplant Model

J. Cools, N. Mentens, P. Vandenberghe, 2018, HemaSphere.

Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia

Rob Pieters, Frank Speleman, Peter Marynen, 2007, Nature Genetics.

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.

P. Marynen, I. Lahortiga, J. Cools, 2007, Haematologica.

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.

S. Aerts, Gert Hulselmans, M. Fiers, 2014, Blood.

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.

P. Marynen, A. Hagemeijer, R. Sciot, 2005, Gastroenterology.

Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate

P. Marynen, R. Sciot, M. Debiec‐Rychter, 2006, Clinical Cancer Research.

Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia

Stein Aerts, Gert Hulselmans, Frank Speleman, 2013, PLoS genetics.

Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent

P. Marynen, D. Gilliland, J. Cools, 2006 .

NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins

K. Bennett, O. Hantschel, Tiziana Girardi, 2014, Haematologica.

PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.

F. Sigaux, J. Soulier, T. Haferlach, 2011, Blood.

PTPN 2 negatively regulates oncogenic JAK 1 in T-cell acute lymphoblastic leukemia

F. Sigaux, J. Soulier, T. Haferlach, 2011 .

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia

A. Ferrando, F. Sigaux, J. Soulier, 2009, Nature Genetics.

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).

Peter Marynen, Jan Cools, Carlos Graux, 2005, Blood.

Activation of FIP 1 L 1-PDGFR requires disruption of the juxtamembrane domain of PDGFR and is FIP 1 L 1-independent

P. Marynen, D. Gilliland, J. Cools, 2006 .

MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context

J. Cools, T. Tousseyn, N. Mentens, 2011, Haematologica.

Fusion of EML 1 to ABL 1 in T-cell acute lymphoblastic leukemia with cryptic t ( 9 ; 14 ) ( q 34 ; q 32 )

Peter Marynen, Jan Cools, Carlos Graux, 2005 .

Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified

P. Gaulard, L. de Leval, S. Demeyer, 2021, Nature Communications.

In vitro validation of gamma-secretase inhibitors for the treatment of T-cell acute lymphoblastic leukemia

P. Marynen, I. Lahortiga, J. Cools, 2007 .

Prediction of Resistance to Small Molecule FLT3 Inhibitors

Doriano Fabbro, Peter Marynen, Pascal Furet, 2004, Cancer Research.

Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large‐cell lymphoma and inflammatory myofibroblastic tumor

P. Marynen, A. Hagemeijer, P. Pauwels, 2002, Genes, chromosomes & cancer.

Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.

P. Marynen, D. Gilliland, J. Cools, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene

L. Michaux, K. Jacobs, J. Cools, 2017, Haematologica.

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia

S. Demeyer, J. Meijerink, E. Radaelli, 2018, Cancer cell.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

P. Marynen, J. Cools, N. Mentens, 2006 .

Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia

A. Ferrando, D. Gilliland, A. Look, 2004, Nature Genetics.

Exome sequencing identifies mutation of the ribosome in T-ALL

S. Aerts, B. Hassan, J. Soulier, 2013 .

Sorafenib is a potent inhibitor of FIP 1 L 1-PDGFR and the imatinib-resistant FIP 1 L 1-PDGFR T 674 I mutant

P. Marynen, J. Cools, N. Mentens, 2006 .

In vitro validation of γ-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia

P. Marynen, M. Odero, L. van Neste, 2008, Haematologica.

JAK3 Mutants Transform Hematopoietic Cells through JAK1 Activation Causing T-Cell Acute Lymphoblastic Leukemia in a Bone Marrow Transplant Mouse Model

K. Jacobs, J. Cools, T. Tousseyn, 2014 .

A new family of small, palmitoylated, membrane‐associated proteins, characterized by the presence of a cysteine‐rich hydrophobic motif

P. Marynen, J. Cools, N. Mentens, 2001, FEBS letters.

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia

A. Ferrando, F. Sigaux, J. Soulier, 2009, Nature Genetics.